With VisiGen Deal Brewing, ABI Continues to Evaluate Next-generation Sequencing Techs | GenomeWeb

A day after announcing that it would make an equity investment in next-generation DNA sequencing technology firm VisiGen Biotechnologies, Applied Biosystems officials said last week that it continues to evaluate other alternative sequencing technologies.

ABI also surprised the market with a relatively strong fiscal 2006 first-quarter, reporting a 6.4-percent increase in revenue and a 55-percent jump in profits.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.